Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis

Journal of Immunology

Volumn 162, Issue 3, 1999, Pages 1818-1826

  Weinberg, Andrew D ^a,d   Wegmann, Keith W ^b,c   Funatake, Castle ^a   Whitham, Ruth H ^b,c  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OX 40 LIGAND; OX 40R PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; FEMALE; HELPER CELL; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD27; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; KINETICS; LIGANDS; LYMPHOCYTE ACTIVATION; MACROPHAGE-1 ANTIGEN; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTORS;

EID: 0033083303     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
2. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
3. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792.
4. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science 265:1225.
5. Cross, A. H., T. J. Girard, K. S. Giacoletto, R. J. Evans, R. M. Keeling, R. F. Lin, J. L. Trotter, and R. W. Karr. 1995. Long-term inhibition of murine EAE using CTL4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:2783.
6. r detected only on CD4 positive T blasts. Mol. Immunol. 24:1281.
7. + T cells with homology to tumor necrosis factor J. Exp. Med. 180:757.
8. Baum, P. R., R. B. Gayle, F. Ramsdell, S. Srinivasan, R. A. Sorensen, M. L. Watson, M. F. Seldin, E. Baker, G. R. Sutherland, K. N. Clifford, et al. 1994. Molecular characterization of murine and human OX-40/OX-40 ligand systems: identification of a human OX-40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 13:3992.
9. + T cells. Int. Immunol. 10:453.
10. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47.
11. Gilfillan, M. C., P. J. Noel, E. R. Podack, S. L. Reiner, and C. B. Thompson. 1998. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J. Immunol. 160:2180.
12. Hurtado, J. C., Y-J. Kim, and B. S. Kwon. 1997 Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158:2600.
13. tax. Mot. Cell. Biol. 11:1313.
14. Stuber, E., M. Neurath, D. Calderhead, H. P. Fell, and W. Strober. 1995. Crosslinking of OX-40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507.
15. Imura, A., T. Hori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura, and T. Uchiyama. 1996. The human OX-40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183:2185.
16. + T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J. Neurosci. Res. 43:42.
17. + spinal cord T cells of Lewis rats with EAE. J. Neurosci. Res. 44:562.
18. Weinberg, A. D., T. Sullivan, M. Lemon, J. J. Wallin, D. N. Bourdette, R. C. Harmon, R. J. Fulton, H. Offner, and A. A. Vandenbark. 1996. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. 2:183.
19. Tittle, T. V., A. D. Weinberg, C. N. Steinkeler, and R. T. Maziarz. 1997. Expression of the T cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 89:4652.
20. Vetto, J. T., S. Lum, A. Morris, M. Sicotte, J. Davis, M. Lemon, and A. Weinberg. 1997. Presence of the T cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head neck cancers. Am. J. Surg. 174:258.
21. Weinberg, A. D., J. J. Wallin, R. E. Jones, T. J. Sullivan, D. N. Bourdette, A. A. Vandenbark, and H. Offner. 1994. Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J. Immunol. 152:4712.
22. Whitham, R. H., C. Nilaver, D. N. Bourdette, and F. J. Seil. 1988. Serum antimyelin antibodies in chronic relapsing EAE. J. Neuroimmunol. 18:155.
23. Brown, A. M., and D. E. McFarlin. 1981. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab. Invest. 45:278.
24. - T lymphocytes. J. Immunol. 127:1420.
25. Whitham, R. H., D. Wingett, J. Wineman, M. Mass, K. Wegmann, A. Vandenbark, and H. Offner. 1997. Treatment of relapsing EAE with T cell receptor Vβ-specific antibodies when proteolipid protein is the autoantigen. J. Neurosci. Res. 45:104.
26. Whitham, R. H., D. N. Bourdette, G. A. Hashim, R. M. Herndon, R.C. Ilg, A. A. Vandenbark, and H. Offner. 1991. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 146:101.
27. Whitham, R. H., B. L. Kotzin, A. C. Buenafe, A. D. Weinberg, R. E. Jones, G. A. Hashim, C. M. Hoy, A. A. Vandenbark, and H. Offner. 1993. Treatment of relapsing experimental autoimmune encephalomyelitis with T cell receptor peptides. J. Neurosci. Res. 35:115.
28. Sedgwick, J. D., A. L. Ford, E. Foulcher, and R Airiess. 1998. Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts. J. Immunol. 160:5320.
29. Ford, A. L., E. Foulcher, F. A. Lemckert and J. D. Sedgwick. 1996. Microglia induce CD4 T lymphocyte final effector function and death. J. Exp Med. 184: 1737.
30. Tan, L., K. B. Gordon, J. P. Mueller, L. A. Matis, and S. D. Miller. 1998. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-γ-activated SJL/J astrocytes. J. Immunol. 160: 4271.
31. Weinberg, A. D. 1998. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol. Med. Today 4:76.
32. + T cells that induce experimental allergic encephalomyelitis. J. Neuroimmunol. 40:57.
33. + T cells in transgenic mice expressing a class II MHC restricted antigen receptor. Nature 341:746.
34. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510.
35. + T cells. J. Immunol. 155:45.
36. Durie, F., W. C. Fanslow, J. Zappone, P. S. Baum, C. Otten, D. Torrance, M. K. Kennedy, and K. M. Mohler. 1996. Conversion of chronic graft-versus-host disease to that of the acute phenotype using in vivo administration of an antibody to OX-40. FASEB (AAI) Conference (New Orleans), Abstr. 2508.
37. Cannella, B., A. H. Cross, and C. S. Raine. 1991. Adhesion-related molecules in the central nervous system: upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab. Invest. 65: 23.